Stock Ratings / Health Care / ENOV / dividends

CDRE (74) ESTA (34) AVR (36) SMTI (57) ⌘ Pro Terminal →

Enovis Corporation (ENOV) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is ENOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Enovis Corporation (NYSE: ENOV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $22.81 (+4.11% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ENOV ranks #444 in composite RQD confidence.

Q: How does ENOV compare to CDRE and ESTA in the Health Care sector?

Within the Health Care sector (Industrial Specialties), ENOV carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -32.7%. By comparison, CDRE (Cadre Holdings Inc.) holds a B grade (74/100 RQD, P/E 30.2x, ROIC 11.0%, cap $1.33B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -15.8%, cap $2.04B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for ENOV?

Per ENOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420800), Enovis Corporation generated $2.25B in revenue (+6.7% YoY), -$1.18B in net income, and $19.9M in free cash flow against $3.83B in total assets and $1.26B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is ENOV trading relative to its 50-day, 200-day, and 52-week technical levels?

ENOV last traded at $22.81 (+4.11% on volume of 1,296,436 shares), positioning the stock +13.99% above its 50-day simple moving average ($20.01) and -1.13% below its 200-day simple moving average ($23.07). Across its 52-week range of $16.70 to $32.41, ENOV sits at the 38.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($20.35 to $25.27).

Q: Does ENOV pay a dividend and is it safe?

Enovis Corporation (ENOV) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$22.81 +4.11% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.94

Enovis Corporation (ENOV) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $1.32B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.94 (+0.55%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENOV)Realized 20D OHLCV Swing Band: ±10.8%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY ENOV SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (24% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$17.69+10.7% Next Q

Q2 (-2Q)

Grade D$19.59+7.6% Next Q

Q3 (-1Q)

Grade D$21.08+8.2% Next Q

Current

Grade D$22.81-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENOV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENOV currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.01) and Max Pain ($23.95) forces dealer call-delta covering toward $34.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENOV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ENOV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENOV)

✓Walkthrough of ENOV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ENOV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.69%📐 HORIZONTAL RANGE

2026-10-30O $22.17H $22.81L $19.83C $22.81VOL 2.52M

RES: $35.64SUP: $16.14SMA50: $20.01SMA200: $23.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENOV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENOV Butterfly Map → + Track ENOV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ENOV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENOV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ENOV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENOV)

Health Care Rank #444 of 1016 ⚔️ CDRE vs ENOV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENOV vs. CDRE, ESTA, AVR, SMTI)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Enovis Corporation (ENOV) ranks #444 by composite RQD confidence (46/100, grade D) and #326 by equity capitalization ($1.32B). Within this direct 5-issuer industry benchmark cohort, SMTI leads on earnings valuation at 8.1x trailing P/E, while SMTI leads on capital efficiency and profitability with 16.3% ROIC and 92.7% gross margin. CDRE currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ENOV at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ENOV ACTIVE Enovis Corporation	D	46/100	—	59.8%	-32.7%	+4.11%	$1.32B	Benchmark Subject
CDRE Cadre Holdings Inc.	B	74/100	30.2x	42.5%	11.0%	+3.81%	$1.33B	/cdre-vs-enov →
ESTA Establishment Labs Holdings Inc.	E	34/100	—	69.3%	-15.8%	-0.81%	$2.04B	/esta-vs-enov →
AVR Anteris Technologies Global Corp.	D-	36/100	—	70.3%	-35.0%	+5.25%	$625.9M	/avr-vs-enov →
SMTI Sanara MedTech Inc.	D+	57/100	8.1x	92.7%	16.3%	+0.11%	$302.4M	/smti-vs-enov →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001420800

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enovis Corporation (ENOV) reported GAAP revenue of $2.25B (+6.7% vs. FY2024 revenue of $2.11B , and +31.7% cumulative change since FY2023) , GAAP net income of -$1.18B, operating cash flow of $217.3M, and free cash flow of $19.9M (+129.6% YoY). On the balance sheet, ENOV closed FY2025 with $3.83B in total assets against $1.26B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.25B	-$1.18B	$217.3M	$19.9M	$3.83B	$1.26B
FY2024 (FY)	2024-12-31	$2.11B	-$825.5M	$113.5M	-$67.2M	$4.72B	$1.31B
FY2023 (FY)	2023-12-31	$1.71B	-$33.3M	$135.0M	$135.0M	—	—

3. ENOV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENOV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Enovis Corporation (NYSE: ENOV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $22.81 (+4.11% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ENOV ranks #444 in composite RQD confidence.

How does ENOV compare to CDRE and ESTA in the Health Care sector?

Within the Health Care sector (Industrial Specialties), ENOV carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 59.8%, and ROIC of -32.7%. By comparison, CDRE (Cadre Holdings Inc.) holds a B grade (74/100 RQD, P/E 30.2x, ROIC 11.0%, cap $1.33B) and ESTA (Establishment Labs Holdings Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -15.8%, cap $2.04B). Among the 5-stock peer group, SMTI leads on earnings multiple (8.1x) while SMTI leads on capital efficiency (16.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENOV?

Per ENOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001420800), Enovis Corporation generated $2.25B in revenue (+6.7% YoY), -$1.18B in net income, and $19.9M in free cash flow against $3.83B in total assets and $1.26B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENOV trading relative to its 50-day, 200-day, and 52-week technical levels?

ENOV last traded at $22.81 (+4.11% on volume of 1,296,436 shares), positioning the stock +13.99% above its 50-day simple moving average ($20.01) and -1.13% below its 200-day simple moving average ($23.07). Across its 52-week range of $16.70 to $32.41, ENOV sits at the 38.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($20.35 to $25.27).

ENOV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ENOV pay a dividend and is it safe?

Enovis Corporation (ENOV) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ENOV RQD Cockpit ENOV 12M Forecast ENOV Earnings & Move ENOV Dividends & DRIP ENOV Insiders & 13F ENOV Whale Options ENOV Profit Sankey ENOV News & Why